Varun Naik

Recent Posts

An Uphill Battle for Biosimilar Adoption in the U.S.

Posted by Varun Naik on Feb 26, 2018 6:00:23 PM

Biosimilars were expected to spark competition and lower prices for branded biologics, but this potential has still been unfulfilled. The U.S. health industry has been relatively slow to adopt biosimilars due to a combination of complex market access tactics employed by branded biologics manufacturers, on-going patent litigation, lack of interchangeability, and a general lack of awareness and acceptance of biosimilars. To date, the FDA has approved nine biosimilars; however, only three biosimilars have launched. The current biosimilars landscape is in stark contrast to the generics market where payers and pharmacy benefit managers promote these cheaper alternatives to reduce healthcare costs.

Read More

Topics: Market Analysis, Pharma, Healthcare, Pharmaceuticals

The Ever Shifting Pharmaceutical Marketplace – Biosimilars and Interchangeability

Posted by Varun Naik on Dec 12, 2016 10:22:27 AM

The FDA recently approved Amjevita (adalimumab-atto), Amgen’s adalimumab biosimilar product for seven inflammatory indications in adult patients1. It was the fourth biosimilar approved by the FDA, and was announced just days after approval was granted for Sandoz’s Erelzi (etanercept-szzs), an Enbrel® biosimilar. Both Enbrel® and Humira® are blockbuster drugs with worldwide revenues over $8.7 and $14 billion respectively and the introduction of related biosimilars will certainly impact their growth potential by providing patients with new and different options and greater access to treatments. Further, biosimilars are expected to generate considerable cost savings for patients and reduce the burden on healthcare expenses.

Read More

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Recent Posts

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.